MaxCyte, Inc. (MXCT)

USD 4.19

(-1.87%)

Market Cap (In USD)

441.97 Million

Revenue (In USD)

41.28 Million

Net Income (In USD)

-37.92 Million

Avg. Volume

429.97 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.165-5.545
PE
-
EPS
-
Beta Value
1.16
ISIN
US57777K1060
CUSIP
57777K106
CIK
1287098
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Maher Masoud
Employee Count
-
Website
https://maxcyte.com
Ipo Date
2021-07-30
Details
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

More Stocks